1. | gmucaria | |
2. | tfeh1389 | |
3. | kotommi7947 | |
4. | gary452849 | |
5. | lukeadlard |
1. | gmucaria | |
2. | tfeh1389 | |
3. | kotommi7947 | |
4. | gary452849 | |
5. | lukeadlard |
1. | gmucaria 03/12/2018 Regeneron and Sanofi Announce Praluent Met Primary Endpoint of Reducing Cardiovascular Events |
2. | gary452849 01/23/2018 Cut to underweight, fun |
3. | tfeh1389 01/29/2018 Take it to the bank news :) - Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion). Company is payi… |
4. | kotommi7947 05/01/2018 Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients |
5. | lukeadlard 04/27/2018 Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER |
6. | gary452849 02/05/2018 Two emerging market drug companies |
7. | lukeadlard 04/25/2018 FDA accepts for review Supplemental Biologics License Application for 0.5 mL dose of Fluzone® Quadrivalent (Influenza Vaccine) in children 6-35 months of age |
8. | gary452849 04/03/2018 Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency has accepted for review the… |
9. | kotommi7947 05/03/2018 Sanofi: Annual General Shareholders' Meeting of May 2, 2018 |
10. | tfeh1389 02/07/2018 LMAO. how did they miss? |